At least on the commercial side the FDA requires that your approval population (“treatment group”) be “representative” of the population who will receive the drug if it’s approved. So you can’t get away with, say, doing your study solely in Chad or Norway as their population distribution (except perhaps by sex) won’t match that of the USA.